Paul Workman FRS FRSC FMedSci (born 30 March 1952) is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of oncology.

The early part of his career (1976–90) was spent establishing and leading the Pharmacology and New Drug Development Laboratory at the Medical Research Council's Clinical Oncology Unit at the University of Cambridge, where he developed new treatments to exploit hypoxic cells in solid tumours and elucidated the enzymes involved in the activation of hypoxia-targeted drugs.

[3] Overall, since 2005, the Cancer Therapeutic Unit has discovered 17 drug candidates, seven of which have progressed to the patient trial stage.

Other contributing factors include running multiple projects on a competitive scale, establishing long-term financial support and – most important – selecting productive and timely industrial collaborations.

[11] Workman is currently working on drugs that block molecules essential for the growth and survival of cancer cells, in particular, molecular chaperones such as Hsp90.